Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

BusinessWeek March 21, 2005 Catherine Arnst	On The Hot Seat At Biogen How Biogen CEO Jim Mullen managed a drug crisis after alarming news broke that the multiple sclerosis drug Tysabri may cause a deadly brain infection.
The Motley Fool June 8, 2010 Ryan McBride	Biogen's CEO Retires, COO to Follow A replacement won't be announced for a few weeks.
Investment Advisor December 2005 Greg B. Scott	Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns.
The Motley Fool August 9, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool June 30, 2010 Ryan McBride	Reports: Biogen Picks Exelixis Chief George Scangos as New CEO George Scangos, a microbiologist by training, has been CEO of the South San Francisco-based cancer drug developer Exelixis since 1996, and takes over at Biogen immediately.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA
BusinessWeek September 23, 2010 Rob Waters	Stem Cells That Save Big Pharma a Bundle Drugmakers hope to save big by using stem cells to test drugs for dangerous side effects long before costly human trials are needed.
The Motley Fool June 30, 2010 Brian Orelli	Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth?
The Motley Fool April 22, 2011 MedCity News	Biogen Idec's MS Drug Appears to Have an Edge Trial results give the company an advantage in oral MS treatments.
The Motley Fool September 8, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool August 19, 2010 Brian Orelli	High Risk, High Reward. At Least It Was Cheap! Biogen licenses a drug to treat ALS.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool May 26, 2004 Charly Travers	Elan and Biogen File for Approval There's a new multiple sclerosis drug on the horizon.
BusinessWeek June 13, 2005 Catherine Arnst	Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins.
The Motley Fool April 29, 2011 Brian Orelli	Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya.
The Motley Fool March 3, 2011 Brian Orelli	3 Cheers for an FDA Rejection German drugmaker Merck said that the Food and Drug Administration had turned down its multiple sclerosis drug cladribine. The pill would have competed with Novartis' Gilenya, which gained FDA approval last year.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool August 28, 2006 Brian Lawler	The Commandments of Biotech Investing Since long-term successful biotech investing requires accurate risk assessment, you must be aware of the risk you're taking on. Just as with any prospective investment, if you diversify your biotech holdings, you can somewhat mitigate these various risks.
BusinessWeek March 14, 2005 Arnst & Barrett	Another Ailing Miracle Drug Biogen's troubles with Tysabri are a setback for immune-system treatments
The Motley Fool February 10, 2010 Brian Orelli	Icahn's Smiling -- Should We Be? Biogen Idec's fourth quarter results must have made Carl Icahn smile. But the guidance for next year gives pause.
The Motley Fool January 25, 2010 Brian Orelli	No Way to Hide This Drug Approval FDA trumps Acorda on its good news. The biotech announced Food and Drug Administration approval of Ampyra, its drug to help multiple sclerosis patients walk better after the markets closed on Friday.
The Motley Fool July 21, 2010 Brian Orelli	Biogen Looks Good Now, but What About Tomorrow? Biogen Idec saw revenue increase 11% and adjusted earnings per share jump almost 75%, which is all well and good, but the longer-term prospects for the company aren't nearly as impressive.
The Motley Fool July 26, 2006 Brian Lawler	Biogen Slows Down Several potential growth drivers should help the biopharma. Ever since the merger with Idec, the company has been fairly well run (absent the Tysabri delays). Investors, take note.
The Motley Fool April 12, 2011 Brian Orelli	How Significant Is 'Statistically Significant' for Biogen? Biogen could have a third multiple sclerosis blockbuster on its hands.
The Motley Fool August 20, 2010 Brian Orelli	This Billionaire Likes Biotech. Should You? It depends on how much you trust management.
The Motley Fool June 5, 2009 Brian Orelli	Failure! Merck said today that rolofylline failed to show an effect in its phase 3 clinical trial in heart failure patients.
The Motley Fool May 26, 2010 Brian Orelli	Blockbuster Drugs Aimed at Busting MS Multiple sclerosis is a large market with more entrants coming.
The Motley Fool March 8, 2005 Charly Travers	After the Crash, Is Biogen IDEC a Buy? Biogen stock plunge may be an overreaction to pulling multiple sclerosis drug Tysabri off the market.
The Motley Fool March 10, 2010 Brian Orelli	You Paid How Much for That? Abbott steps up where Biogen Idec wouldn't.
The Motley Fool October 27, 2010 Brian Orelli	Biogen Idec's Fight-Back Plan Novartis' Gilenya is coming, but Biogen has a backup plan.
The Motley Fool December 20, 2007 Brian Orelli	2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something.
The Motley Fool March 29, 2010 Brian Orelli	Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data.
The Motley Fool January 5, 2010 Brian Orelli	Biogen Idec's CEO Calls It Quits And the market seems to be saying to him don't let the door hit you on the way out.
The Motley Fool April 21, 2011 Brian Orelli	Tysabri Means Everything to Biogen and Elan ... for Now It's rare to find a drug that affects two companies as much as Tysabri does Biogen Idec and Elan.
The Motley Fool June 8, 2010 Brian Orelli	Injecting Uncertainty Into the Multiple Sclerosis Market Novartis' oral MS drug could be a blockbuster -- if it can get past the FDA.
The Motley Fool February 18, 2004 Jeff Hwang	Elan's Early Submission Elan and Biogen Idec will submit a multiple sclerosis treatment ahead of schedule.
The Motley Fool January 21, 2011 Brian Orelli	Trouble in Tysabri Land? Patient additions for a drug from Biogen Idec and Elan are slowing down.
The Motley Fool June 17, 2004 Brian Gorman	Genentech's Unique Drug Genentech and Biogen Idec's Phase II trial demonstrating Rituxan's effectiveness in treating moderate-to-severe rheumatoid arthritis was enshrined in the prestigious pages of the New England Journal of Medicine, adding heft to the study's results.
The Motley Fool June 3, 2010 Brian Orelli	When All Else Fails, Sue Your Competitors Biogen thinks its patent covers its competitors' drugs in addition to Avonex and has filed a lawsuit demanding royalties from its competitors.
The Motley Fool July 24, 2007 Brian Lawler	Biogen's Steady Growth Biogen reports another good quarter of growth, both top- and bottom-line.
The Motley Fool May 5, 2006 Stephen D. Simpson	Biogen Idec Needs a Booster Tysabri had better come back strong, or growth could come up short for this biotech. Investors, take note.
The Motley Fool February 8, 2005 Charly Travers	Good Prognosis for Biogen IDEC Blockbuster products help the biotech firm continue its stellar performance.
The Motley Fool February 2, 2011 Brian Orelli	A Deeper Dive Into Biogen's Revenue Growth On the surface, it looks like Biogen Idec is handling the entrance of Novartis' new oral multiple sclerosis drug, Gilenya, quite well. The real picture is a little bleaker.
BusinessWeek June 13, 2005 Arlene Weintraub	Why Biotech Stocks Are Sedated Biotech might seem like a can't-miss investing opportunity but many investors are taking a pass on biotech, even amid bona fide scientific advances.
The Motley Fool March 11, 2005 Karl Thiel	Better Times at Biogen IDEC Is now the time to buy this pharmaceutical?
The Motley Fool September 14, 2006 Brian Lawler	Good Buy for Biogen Idec The biotech's past success bodes well for its plans for a new blood pressure drug. Investors, take note.
The Motley Fool March 15, 2007 Brian Lawler	Dueling Fools: Elan Bear How do you bring an Elan bear out of hibernation? Combine a crushing debt load, a huge cloud of uncertainty over its lead developmental drug program, and the launch of a new product that won't bring in enough revenue to sustain the current valuation, et voila! A bear is born.
The Motley Fool December 4, 2009 Brian Orelli	Our Final Offer (Maybe)! That's a FACT! Biogen ups its bid for Facet.
The Motley Fool November 26, 2007 Brian Lawler	Biogen Plays Deal Maker Biogen Idec signs a drug development deal with Swiss-based Neurimmune Therapeutics worth up to $380 million. Investors, take note.
The Motley Fool October 16, 2007 Brian Lawler	Questions Surround a Biogen Deal Rumors swirl around Biogen after it publicly announces that it's for sale. Investors, take note.